Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Current Issue
Archive
Reports
2021 Gene Therapy Report
2021 Biologics Report
2021 Sterile Drug Products Report
2021 API Market Report
2020 OSD Market Report
Community
Company A to Z
More+
Staffing
Media Kit
Investment
188 Articles Available
1
8
Can't find what you're looking for? Try our
advanced search
.
High Potency
Streamlining Highly Potent Drug Commercialization
PAO-04-21-CL-04
COVID-19 Impacts
Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?
PAO-03-21-NI-01
The Future of Healthcare
How Does Dynamk Capital Envision the Future of the Pharma/Biopharma Industry?
PAP-Q4-20-RT2-013
Investment
SEQENS Invests in New Technologies
PR-M11-20-015
Investment
Intuitive Launches $100 Million Venture Capital Fund
PR-M10-20-17
Strategy
Vetter Continues its Long-term Investment Strategy to Sustain Future Growth
PR-M10-20-13
Northern Ireland
COVID-19 and the Growing Need for Dual-Source Supply Chains
PAP-Q3-20-CL-022
Medical Devices
Investing with a Focus on Medical Devices and Digital Health
PAP-Q3-20-CL-023
Investment
Altis Biosystems Announces Completion of a $3.1 Million Seed Investment Led by VentureSouth
PR-M08-20-NI-18
Financing
PMV Pharma Closes $70 Million in Series D Financing
PR-M08-20-NI-07
COVID-19 Vaccine Funding
Sanofi and GSK Selected for Operation Warp Speed to Supply United States Government with 100 Million Doses of COVID-19 Vaccine
PR-M08-20-NI-05
Investment
AlloVir Announces Pricing of Upsized Initial Public Offering
PR-M08-20-NI-04
Investment
DFC to Sign Letter of Interest for Investment in Kodak’s Expansion Into Pharmaceuticals
PR-M08-20-NI-01
Antibiotics
Sandoz Announces Plans for Joint Investment to Help Strengthen Future of Antibiotics Manufacturing in Europe
PR-M07-20-NI-38
Funding
Blackstone Announces $4.6 Billion Final Close of Life Sciences Fund
PR-M07-20-NI-012
Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus and Influenza Vaccines
PR-M07-20-NI-010
COVID-19 Vaccine Manufacturing
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate
PR-M07-20-NI-007
Funding
Novavax Announces $1.6 Billion Funding from Operation Warp Speed
PR-M07-20-NI-006
CDMO
Positioning a CDMO to Meet Future Needs
PAP-Q2-20-CL-006
Funding
Cyclica Raises CAD$23 Million in a Series B Financing to Create the Biotech Pipeline of the Future
PR-M06-20-NI-031
Capacity Expansion
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
PR-M06-20-NI-029
IPO
Vaxcyte Announces Pricing of Upsized Initial Public Offering
PR-M06-20-NI-018
Funding
SiO2 Materials Science Receives $143 Million Contract from U.S. Government
PR-M06-20-NI-009
Athira Pharma Closes $85 Million Series B Financing
PR-M06-20-NI-007
1
8
»
